Clinical Trial Update: A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent® [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study comparing QL2108 to Dupixent (dupilumab) in individuals with atopic dermatitis; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)
• QL2108

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED